Does BCBS of Michigan Cover GLP-1? Diabetes, Weight Loss, Appeals

Blue Cross Blue Shield of Michigan does cover GLP-1 medications when they are prescribed to treat Type 2 diabetes, but it has eliminated coverage of GLP-1 drugs prescribed for weight loss on most of its commercial plans. Whether your prescription is paid for comes down to two things: the diagnosis on the prescription and the type of plan you have.

GLP-1s Prescribed for Type 2 Diabetes

BCBSM and its HMO affiliate, Blue Care Network, continue to cover Ozempic (semaglutide), Mounjaro (tirzepatide), Rybelsus (oral semaglutide), Trulicity (dulaglutide), and liraglutide when they are prescribed for Type 2 diabetes.¹²

Two older diabetes GLP-1s, Bydureon BCise and Byetta, came off the preferred drug list on January 1, 2026. Members taking either are directed to switch to one of the covered alternatives above.³

How Prior Authorization Works

Since August 2023, every GLP-1 prescribed for diabetes on a BCBSM or BCN commercial plan requires prior authorization. In practice, most prescriptions clear without any paperwork. At the pharmacy counter, the system checks whether the member has a Type 2 diabetes diagnosis code in medical claims from the previous twelve months or a recent pharmacy claim for another diabetes medication. If either shows up, the prescription is filled.⁴

When nothing qualifying is found, the prescriber submits a short attestation confirming Type 2 diabetes. BCBSM does not require clinical documentation at this step; the office simply verifies the diagnosis. Prediabetes and obesity do not qualify under the diabetes pathway.⁴

GLP-1s Prescribed for Weight Loss

BCBSM ended coverage of Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide) for weight loss on fully insured large group commercial plans. The termination took effect January 1, 2025, or on the employer group’s 2025 renewal date if that came later in the year. Members who continue filling these prescriptions for weight loss pay the full cost.²⁵

On January 1, 2026, Saxenda was pulled from the clinical, custom, and preferred drug lists entirely. For members whose plans still include weight loss drug coverage, the covered options are phentermine, phentermine/topiramate ER, Wegovy, and Zepbound. BCBSM notes that “weight loss coverage is dependent on the member’s benefit plan and may not be covered.”³

Your Plan Type Decides the Answer

The weight loss exclusion does not sweep every BCBSM member the same way. What kind of plan you have matters.

Fully Insured Large Group Commercial

These members bear the full impact. Wegovy, Zepbound, and Saxenda appear as non-covered drugs on the preferred, clinical, and HMO custom drug lists.⁶⁷

Self-Funded (ASO) Employer Plans

Self-funded employers that use BCBSM only to administer benefits can still choose to cover GLP-1 weight loss drugs. The 2024 provider alert stated that these groups may keep their existing prior authorization criteria and are not subject to the mandatory termination. If your coverage runs through a large employer, check your specific plan documents.²

MESSA

The Michigan Education Special Services Association, which covers many school employees through BCBSM, was initially outside the termination. As of October 2025, MESSA’s own policy states that it does not cover Saxenda, Wegovy, or Zepbound for weight loss or for other diagnoses such as sleep apnea. Ozempic, Mounjaro, Rybelsus, and Trulicity remain covered for diabetes.⁸

Small Group and Individual Plans

BCBSM’s provider documentation names “fully insured large group commercial members” as the group affected and does not address small group plans separately. Small employer plans and individual marketplace plans generally follow standardized BCBSM formularies without employer-level customization, so members on those plans usually cannot override a formulary exclusion.²

Medicare Advantage and Part D

BCBSM’s Medicare plans cover GLP-1s for Type 2 diabetes, consistent with federal Medicare rules. Medicare does not generally cover GLP-1s for weight loss. A federal demonstration called the Medicare GLP-1 Bridge is scheduled to run from July 1, 2026, through December 31, 2027, providing a separate pathway for beneficiaries seeking GLP-1s for weight management. Humana administers the demonstration as a central processor, and it operates outside standard Part D.⁹

Michigan Medicaid

Michigan Medicaid follows its own rules. Under Public Act 22 of 2025, effective January 1, 2026, Saxenda, Wegovy, and Zepbound require prior authorization when prescribed for obesity. Coverage is limited to patients classified as morbidly obese, requires documented failure of other clinically appropriate weight loss interventions including preferred anti-obesity agents, and is framed as a step to prevent the need for higher-cost bariatric surgery. Saxenda and Wegovy moved to non-preferred status, raising copayments from $1 to $3 for affected beneficiaries. Prior authorizations approved before January 1, 2026, remain valid for the balance of their six-month term.¹⁰

Zepbound and Mounjaro Are Not Interchangeable for Coverage

Both drugs contain tirzepatide, but they carry different FDA-approved indications and sit in different coverage categories at BCBSM. Mounjaro is approved for Type 2 diabetes and remains covered. Zepbound is approved for weight management and is excluded on the affected plans alongside Wegovy and Saxenda. BCBSM’s 2024 transitional criteria stated plainly that Zepbound was “not covered for members with Type 2 diabetes,” so a prescriber cannot simply switch products to route around the exclusion.⁷²

What Happens on Appeal

Members who have been denied GLP-1 weight loss coverage can request external review through the Michigan Department of Insurance and Financial Services. Recent outcomes show a clear pattern: the plan documents drive the decision.

In File No. 234270-001, decided April 1, 2025, the DIFS Director reversed a Wegovy denial because BCBSM’s own Saver Rx drug list, updated as recently as February 7, 2025, still listed Wegovy as a “nonpreferred drug” rather than an excluded one. The member’s contract required coverage of drugs on the formulary, so the denial was inconsistent with the plan terms and BCBSM was ordered to provide coverage.¹¹

In File No. 235707-001-SF (June 23, 2025), a self-funded plan member won reinstatement of Zepbound after BCBSM denied continuation because the patient’s BMI had dropped below 35 during treatment. An independent review organization found the initial BMI of 38.4 established medical necessity and that current BMI alone should not end ongoing therapy.¹²

When plan language clearly excludes GLP-1 weight loss drugs, denials have been upheld. In File No. 234317-001 (May 13, 2025), a request for Wegovy to treat obesity and binge eating disorder was denied because the drug list expressly excluded Wegovy.¹³ In File No. 239833-001 (October 13, 2025), a member who had lost 67 pounds on GLP-1 therapy was denied continued Zepbound coverage because the benefit certificate contained an express GLP-1 weight loss exclusion effective at the employer’s 2025 renewal.¹⁴ File No. 235193-001 reached the same result on a Simply Blue HSA plan whose language specifically excluded “weight loss prescription drugs containing Glucagon-Like Peptide-agonist (GLP-1) products.”¹⁵

Before filing an external review, pull your benefit certificate and your plan’s current drug list. If either document still lists the drug as covered, even as nonpreferred, that inconsistency is the argument that has worked.

Why BCBSM Made the Change

BCBSM cited both cost and clinical data. GLP-1 claims hit $1.1 billion in 2024, a 29 percent jump over 2023, and overall pharmacy claims ran nearly 15 percent higher year over year. Between 2022 and 2023, GLP-1 costs alone grew by more than $350 million. BCBSM noted that all claims it pays, averaging $100 million a day, factor into future premiums.¹

The insurer also pointed to a Blue Health Intelligence study finding that 58 percent of patients taking GLP-1s for weight loss discontinued use before achieving a clinical benefit, with more than 30 percent dropping out after just four weeks. BCBSM said the exclusion was intended to preserve access for patients with Type 2 diabetes who depend on these medications and that more research is needed on whether GLP-1 weight loss treatment reduces medical costs over time.¹

1
BCBSM MiBluedaily. Why We Are Changing Coverage of GLP-1 Drugs for Weight Loss
2
BCBSM Provider Info. Drug Coverage Changes for GLP-1 Weight Loss Drugs, Commercial
3
BCBSM Provider Info. Drug Coverage Changes Effective January 1, 2026
4
MCT2D.org. BCBSM New Prior Authorization Criteria for GLP-1 RAs
5
Fierce Healthcare. Blue Cross Blue Shield of Michigan Pulling Back GLP-1 Coverage
6
BCBSM. Preferred Drug List
7
BCBSM. Clinical Drug List Formulary
8
MESSA. Weight Loss
9
CMS. Medicare GLP-1 Bridge – Information for Part D Plans
10
Michigan MDHHS. Numbered Letter L-25-73 Pharmacy
11
Michigan DIFS. BCBSM File No. 234270-001
12
Michigan DIFS. BCBSM File No. 235707-001-SF
13
Michigan DIFS. BCBSM File No. 234317-001
14
Michigan DIFS. BCBSM File No. 239833-001
15
Michigan DIFS. BCBSM File No. 235193-001